TP53 and neoplasm: Using a panel of clinically representative p53-null murine mammary models that capture both molecular and tumor immune microenvironment diversity in immunotherapy-resistant TNBC, we found that only a subset demonstrated reproducible abscopal effects after RT + ICI.